- Home
- GENK vs CLNN Comparison
GENK vs CLNN Comparison
Compare GENK & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- CLNN
- Stock Information
- Founded
- GENK 2011
- CLNN 2012
- Country
- GENK United States
- CLNN United States
- Employees
- GENK N/A
- CLNN N/A
- Industry
- GENK Restaurants
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- CLNN Health Care
- Exchange
- GENK Nasdaq
- CLNN Nasdaq
- Market Cap
- GENK 27.9M
- CLNN 26.1M
- IPO Year
- GENK 2023
- CLNN N/A
- Fundamental
- Price
- GENK $4.37
- CLNN $2.83
- Analyst Decision
- GENK Strong Buy
- CLNN Strong Buy
- Analyst Count
- GENK 3
- CLNN 5
- Target Price
- GENK $12.17
- CLNN $50.20
- AVG Volume (30 Days)
- GENK 60.3K
- CLNN 51.0K
- Earning Date
- GENK 05-13-2025
- CLNN 05-07-2025
- Dividend Yield
- GENK N/A
- CLNN N/A
- EPS Growth
- GENK 62.05
- CLNN N/A
- EPS
- GENK 0.13
- CLNN N/A
- Revenue
- GENK $208,380,000.00
- CLNN $342,000.00
- Revenue This Year
- GENK $20.48
- CLNN N/A
- Revenue Next Year
- GENK $21.64
- CLNN $2,066.67
- P/E Ratio
- GENK $35.48
- CLNN N/A
- Revenue Growth
- GENK 15.12
- CLNN N/A
- 52 Week Low
- GENK $3.99
- CLNN $2.57
- 52 Week High
- GENK $13.12
- CLNN $9.20
- Technical
- Relative Strength Index (RSI)
- GENK 40.66
- CLNN 34.63
- Support Level
- GENK $3.99
- CLNN $2.76
- Resistance Level
- GENK $4.29
- CLNN $3.18
- Average True Range (ATR)
- GENK 0.43
- CLNN 0.25
- MACD
- GENK 0.01
- CLNN 0.05
- Stochastic Oscillator
- GENK 29.28
- CLNN 38.33
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.